ODAM and cancer: ODAM was also found to be overexpressed in several cancers of epithelial origin, such as gastric, breast, salivary gland, trachea, and colorectal cancers indicating its potential both as a biomarker for prognosis and therapeutic target (Aung et al., 2006; Kestler et al., 2008; Siddiqui et al., 2009; Kestler et al., 2011; Yu et al., 2016).